Propofol causes pain on intravenous injection in 28 to 90% of patients. A number of techniques have been tried to minimize propofol-induced pain, with variable results. In a randomized, double-blind, placebo-controlled trial, we compared the efficacy of ephedrine 30 µg/kg pretreatment to lignocaine 40 mg for prevention of propofol-induced pain. Ninety-three adult patients, ASA 1 and 2, undergoing elective laparoscopic cholecystectomy were randomly assigned to three groups of 31 each. Group 1 received normal saline, group 2 received lignocaine 2% (40 mg) and group 3 received 30 µg/kg ephedrine. All pretreatment drugs were made up to 2 ml. Pain at the time of propofol injection was assessed on a four-point scale: 0=no pain, 1=mild pain, 2=moderate pain, and 3=severe pain. Twenty-seven patients (87%) of ephedrine pretreatment patients had pain during intravenous injection of propofol as compared to 24 (77%) in the normal saline group. In the lignocaine group, propofol-induced pain was observed in only 13 (42%) when compared with other study groups (P<0.05). Pretreatment with ephedrine 30 µg/kg did not attenuate pain associated with intravenous injection of propofol, nor did it improve haemodynamic stability during induction. However, pretreatment with 2% lignocaine (40 mg) was effective in attenuating propofol-associated pain.
Propofol, with its smooth induction and rapid recovery profile, has become a popular drug in modern anaesthetic practice. However, pain on injection of propofol, which has been reported to occur in 30 to 90% of patients, is a major drawback to its use 1 . Profound pain due to propofol injection has been reported to even trigger myocardial ischaemia in a patient with suspected phaeochromocytoma 2 . Many strategies have been tried to reduce pain associated with intravenous propofol injection with variable success (e.g. injection into large veins, warming or cooling the solution, diluting with cold saline, and pretreatment with opioids, lignocaine, magnesium, metoprolol or thiopentone [3] [4] [5] [6] [7] .
Recently, Cheong and co-workers reported that pre-treatment with ephedrine attenuated the pain associated with propofol injection; along with mini-mizing the haemodynamic changes associated with propofol 8 . In this randomized, double-blind, placebocontrolled study, we compared the efficacy of pretreatment with ephedrine with that of lignocaine in reducing pain associated with intravenous (IV) propofol and observed their effect on haemodynamics.
MATERIALS AND METHODS
Following permission from our institutional ethical and research committee and written informed consent from patients, this prospective, double-blind study was conducted in a randomized fashion. Patients having difficulty in communication, anticipated difficulty in intubation or those who could not be intubated at the first attempt were excluded from the study.
Assuming that the incidence of pain following IV propofol is 70%, to have 80% power (α=0.05) to detect a reduction to 35%, one would need to study 31 patients in each group. Therefore this study consisted of 93 ASA physical status 1 or 2 adult patients between the ages of 18 and 50 years undergoing elective laparoscopic cholecystectomy. Patients were randomly assigned into three groups of 31 each using a computer-generated table of random numbers.
Patients received pretreatment solutions one minute before induction. Group 1 (NS): normal saline Group 2 (L): lignocaine 2% (40 mg) Group 3 (E): ephedrine 30 µg/kg.
Patients were premedicated with oral lorazepam 2 mg and ranitidine 150 mg two hours before induction of anaesthesia. After instituting electrocardiogram, noninvasive arterial blood pressure and pulse oximetry monitoring, an 18-gauge IV cannula was inserted into the dorsum of both hands. One cannula was used for infusion of IV fluids, and the other for administration of drugs.
An independent anaesthetist prepared the pretreatment solutions and the investigators were blinded to the contents. All pre-treatment drugs were made into 2 ml and loaded in a 5 ml syringe and were given over three seconds. One minute after pretreatment, 25% of the total calculated dose of propofol was administered over five seconds. The induction dose of propofol (PROPOFOL™ 1%, Claris Lifesciences Ltd) was 2.5 mg/kg. Patients were asked whether they felt any pain or discomfort during administration of propofol. An independent anaesthetist who was unaware of the group to which the patient had been allocated assessed the level of pain. All study drugs were kept at room temperature and used within 30 minutes of preparation.
Assessment of pain was done by using a four-point scale: 0=no pain, 1=mild pain (pain reported only in response to questioning without any behavioural signs), 2=moderate pain (pain reported in response to questioning and accompanied by a behavioural sign or pain reported spontaneously without questioning) and 3=severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal or tears) 9 .
The remaining dose of propofol was administered via an IV infusion over 15 to 20 seconds. Endotracheal intubation was performed three minutes after administration of vecuronium 0.1 mg/kg. Therefore intubation was performed approximately four minutes and 30 seconds after administration of the study drugs. Anaesthesia was maintained with 67% nitrous oxide in oxygen, propofol and fentanyl. Heart rate (HR) and non-invasive automated systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded before the administration of the pretreatment solution (baseline), before laryngoscopy, and one and five minutes after intubation.
The incidence of pain vs no pain was analysed by Z tests, whereas severity of pain (mild, moderate and severe) was analysed by Fisher's Exact test. Analysis of haemodynamic data was performed using repeated measures analysis of variance. The package SPSS 9.0 (SPSS Inc, Chicago, IL) was used for statistical analysis. P<0.05 was considered significant.
RESULTS
All three groups were comparable with respect to demographic characteristics (Table1). The overall incidence of pain during intravenous injection of propofol in the various groups is shown in Table 2 . In the L group 13 (42%) of the patients had pain during IV propofol compared to 24 (77%) and 27 (87%) observed in the NS and E groups respectively (P<0.05).
Lignocaine pre-treatment also decreased the severity of pain when compared to NS group (P<0.05). Ephedrine pre-treatment was ineffective in attenuating pain during IV injection of propofol (P>0.05); however, ephedrine pre-treatment reduced the severity of pain when compared to NS group ( There were no adverse events such as dysrhythmias, severe hypertension or hypotension defined as a change in SBP by 30% of the baseline value. No complications such as oedema, or wheal and flare response were observed at the injection site within the first 24 hours after the operation.
Baseline values of HR, SBP, DBP were comparable in all the groups (Table 3 ). In the ephedrine group an insignificant increase in the HR was observed before laryngoscopy, whereas in all other study groups HR decreased when compared to baseline (P>0.05). SBP and DBP recorded before laryngoscopy decreased in all the groups when compared to baseline (P<0.05). Significant increases in HR, SBP and DBP were observed at one minute after intubation in the ephedrine group when compared with other groups, where a significant increase was observed only in the DBP (P<0.05). Inter-group comparisons between Data are presented as either number of patients or mean±SD. groups L and E revealed an increase in SBP and DBP one minute after intubation in the ephedrine group (P<0.05).
DISCUSSION
We observed that pretreatment with ephedrine 30 µg/kg did not decrease the incidence of pain associated with IV propofol injection when compared to lignocaine 40 mg (P>0.05); however, ephedrine pretreatment reduced the severity of pain when compared to NS group (P<0.05). Lignocaine pre-treatment was effective in attenuating both the incidence and the severity of pain associated with IV propofol injection (P<0.05).
Pain vs no pain was compared using a Z test, which is a parametric test used when the distribution is normal, and in this case we could calculate the power of the test. Our study had sufficient power to exclude only a 50% or more reduction in incidence (i.e. from 70% to 35%). Therefore we could not exclude a smaller effect of ephedrine on the incidence of pain. The severity of pain (mild, moderate and severe) was analysed using Fisher's Exact test, which is a non-parametric test. We did not estimate the power to detect differences in severity of pain. We also performed a large number of comparisons, increasing the chance of a type 1 error. These are limitations of our study, which would have been improved by including more patients.
Propofol, a frequently used IV anaesthetic, with a rapid onset and a short duration of action, causes pain on injection in 28 to 90% of patients 1 . Propofol belongs to the group of phenols that can irritate the skin, mucous membrane and venous intima 10 . It may also activate the kallikrein-kinin system and release bradykinin, thereby producing venous dilatation and increased permeability. This may increase the contact between the aqueous phase of propofol and free nerve endings resulting in pain on injection 4, 11 .
Various methods have been used for reducing pain during IV injection of propofol. These include using larger veins; decreasing the rate of injection; injecting propofol into a fast running IV infusion; diluting it with 5% glucose or 10% intralipid; prior injection of lignocaine, alfentanil, fentanyl, or thiopentone; injecting cold saline at 4°C before propofol; discon- tinuing fluid during the injection; mixing lignocaine in propofol; and cooling propofol to 4°C [4] [5] [6] 12, 13 . Ephedrine is an indirectly acting synthetic noncatecholamine that stimulates both α and β receptors. Onset of action of IV ephedrine is within one minute 14 . The cardiovascular effects of ephedrine resemble those of adrenaline, but its systemic blood pressure elevating response is less intense and lasts approximately ten times longer 15 . Cheong and coworkers suggested that endogenous noradrenaline released by ephedrine might reduce the effect of bradykinin and thus result in attenuation in propofol associated pain 8 . Greenberg and co-workers have reported that bradykinin inhibits noradrenaline efflux from sympathetic nerve terminals 16 .
In their recent study, Cheong and co-workers pretreated their patients with ephedrine in doses of 30 µg/kg, 70 µg/kg, 110 µg/kg and 150 µg/kg respectively, and observed that ephedrine pretreatment reduced the incidence and severity of propofol-induced pain 8 . Cheong et al observed a significant reduction in MAP before intubation in placebo and lignocaine groups when compared to ephedrine groups. They further observed significant increases in MAP and HR following intubation in the ephedrine pretreated groups in the doses of 110 µg/kg and 150 µg/kg; however, ephedrine in doses of 30 µg/kg and 70 µg/kg could prevent propofol-induced hypotension before intubation, and did not produce significant haemodynamic changes compared with other groups after intubation 8 . Contrary to the observations of Cheong et al, we observed that pretreatment with ephedrine 30 µg/kg resulted in an insignificant increase in HR, and a significant decrease in SBP and DBP before laryngoscopy, along with significant increase in the HR, SBP and DBP one minute after intubation. The difference in the results could be due to the difference in the timing of pretreatment, because our pretreatment was one minute prior to propofol whereas Cheong et al administered ephedrine 30 seconds prior to propofol administration.
In conclusion, pretreatment with ephedrine 30 µg/kg does not appear to significantly decrease the incidence of propofol-induced pain, nor does it appear to improve haemodynamic stability during induction with propofol. However, it reduces the severity of propofol-induced pain. Pretreatment with 2% lignocaine (40 mg) is effective in decreasing both the incidence and severity of propofol-associated pain.
